-
Citi Raises Watson Pharmaceuticals Target from $67 to $72
Thursday, May 26, 2011 - 6:12am | 20Citi is raising its PT on Watson Pharmaceuticals (NYSE: WPI) from $67 to $72.
-
Tomorrow's Pre-Market Data Release 05-25-2011
Wednesday, May 25, 2011 - 6:39pm | 920Cusick's Corner The market stayed...constructive but still not able to garner momentum to the upside. The bulls by no means are out of the woods, but the market is setting up for a potential pop, that's if the data that comes out pre-market tomorrow, Personal Income and Spending, does not raise...
-
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad
Wednesday, May 25, 2011 - 4:45pm | 122Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of...
-
Intra-Day Reversal In Amarin
Wednesday, May 25, 2011 - 3:51pm | 71Shares of biotech firm Amarin, Inc. (NASDAQ: AMRN) have been on fire over the last few months, as the company has reported positive Phase III trial data for its cardiovascular drug AMR101. The shares are lower on Wednesday, however, after spending a good part of the day trading higher. AMRN is...
-
Calls Purchased on Elan Corporation
Wednesday, May 25, 2011 - 2:09pm | 136Shares of Elan Corporation (NYSE: ELN) are higher on the session by 5.59%, currently trading at $8.88. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today. A...
-
Amarin Continues To Rise; Profiled On Fast Money
Wednesday, May 25, 2011 - 1:23pm | 181Amarin Corp. (NASDAQ: AMRN) released positive trial data on its leading drug candidate AMR101 on April 18th. The Phase III trial, known as ANCHOR, was geared towards the treatment of cardiovascular disease and met all of its primary and secondary endpoints. Another Phase III trial, MARINE,...
-
Calls Purchased on Watson Pharmaceuticals, Inc.
Wednesday, May 25, 2011 - 1:08pm | 131Shares of Watson Pharmaceuticals, Inc. (NYSE: WPI) are higher on the session by 0.63%, currently trading at $62.22. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name...
-
Calls Purchased on Watson Pharmaceuticals, Inc.
Wednesday, May 25, 2011 - 10:34am | 119Shares of Watson Pharmaceuticals, Inc. (NYSE: WPI) are higher on the session by 0.89%, currently trading at $62.39. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name...
-
Abbott Gets Ce Mark For Realtime Molecular Test For Cyto
Wednesday, May 25, 2011 - 9:05am | 220Abbott (NYSE: ABT) announced it has received CE Mark in the European Union to market its RealTime PCR (polymerase chain reaction) molecular diagnostic test for cytomegalovirus DNA quantitation in human plasma or whole blood. Approximately eighty percent of healthy adults over 40 carry the...
-
Citi Comments On Endo Pharmaceuticals Price Target
Wednesday, May 25, 2011 - 8:42am | 151According to Citi, Endo Pharmaceuticals Holdings (NASDAQ: ENDP) price target is $48. Citi said that it arrives at its $48 price target for Endo based on a relative 2012 P/E multiple compared to the specialty pharmaceutical peer group. “Our relative P/E valuation assumes Endo trades at ~9.3x our...
-
MLV Reiterates Buy Rating On Vivus
Wednesday, May 25, 2011 - 8:29am | 75According to MLV, Vivus (NASDAQ: VVUS) Buy rating is reiterated. MLV said that it reiterates its BUY rating and $16 price target. “As a reminder, VVUS plans to conduct a retrospective fetal outcomes study using existing US electronic healthcare databases. The FORTRESS study will analyze the...
-
Mylan Launches Generic Version of Roxicodone Tablets
Wednesday, May 25, 2011 - 8:19am | 114Mylan (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone Hydrochloride Tablets USP, 5 mg, 15 mg and 30 mg, based on a development and supply agreement with Coastal Pharmaceuticals. This product is the generic version of Xanodyne's Roxicodone®, a...
-
Benzinga's Top Pre-Market NASDAQ Losers
Wednesday, May 25, 2011 - 8:17am | 128Akorn Inc (NASDAQ: AKRX) dipped 4.41% to $6.72 in the pre-market session. AKRX intends to offer $100 million principal amount of Convertible Senior Notes due 2016 . Costco Wholesale Corporation (NASDAQ: COST) dropped 2.89% to $79 in the pre-market trading. Costco reported a 5.9% rise in its fiscal...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Wednesday, May 25, 2011 - 8:10am | 151California Pizza Kitchen Inc (NASDAQ: CPKI) shares advanced 12.51% to $18.80 in the pre-market session. CPKI agreed to sell itself to Golden Gate Capital for about $470 million. VIVUS Inc (NASDAQ: VVUS) shares advanced 4.29% to $8.75 in the pre-market session. VVUS announced positive results from...
-
AMRI to Receive Milestone Payment from Bristol-Myers Squibb for the Initiation of a Phase II Study
Wednesday, May 25, 2011 - 8:02am | 145AMRI (NASDAQ: AMRI) today announced that it will receive a $3 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) resulting from a recently initiated Phase 2 clinical trial of an AMRI compound exclusively licensed to Bristol-Myers Squibb. This is the sixth milestone payment...